LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Inicio・Lista de Acciones・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Cerrado

SectorSalud

1.62 0.62

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.6

Máximo

1.6600000000000001

Métricas clave
By Trading Economics
Ingresos	-2.8M -16M
Ventas	-8.7M 5.5M
Margen de beneficio	-282.723
Empleados	81
EBITDA	-4.2M -15M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+137.89% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	30M 682M
Apertura anterior	1
Cierre anterior	1.62

Noticias sobre sentimiento de mercado

By Acuity

72%

28%

315 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

0.6863 / 0.72 Soporte y Resistencia

Lexicon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 mar 2026, 22:42 UTC

Ganancias

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar 2026, 21:40 UTC

Ganancias

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar 2026, 23:56 UTC

Charlas de Mercado

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 mar 2026, 23:42 UTC

Charlas de Mercado

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar 2026, 23:38 UTC

Charlas de Mercado

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

17 mar 2026, 23:24 UTC

Charlas de Mercado

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar 2026, 22:22 UTC

Charlas de Mercado

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar 2026, 22:20 UTC

Ganancias

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar 2026, 22:07 UTC

Ganancias

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar 2026, 22:05 UTC

Ganancias

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar 2026, 22:04 UTC

Ganancias

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar 2026, 22:03 UTC

Ganancias

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar 2026, 22:01 UTC

Ganancias

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar 2026, 21:26 UTC

Ganancias

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar 2026, 21:09 UTC

Ganancias

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar 2026, 21:08 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:07 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:06 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q EPS 82c >ATD.T

17 mar 2026, 21:05 UTC

Ganancias

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Lexicon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

137.89% repunte

Estimación a 12 meses

Media 3.83 USD 137.89%

Máximo 6 USD

Mínimo 1 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6863 / 0.72Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentimiento

By Acuity

315 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.